about
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada.Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review.Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study.Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugsAustralia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling studyA global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs – do gender differences vary by country-level indicators?Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyParitaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyAcceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in AustraliaDirect-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysisCombined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling studyAdherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapyHepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysisElbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trialTreatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infectionAssociations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysisFrequency of injecting among people who inject drugs: A systematic review and meta-analysisThe prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysisDirect-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, CanadaGlobal systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence
P50
Q33795847-87409590-50A8-4BA6-AFE8-47B86C0C6397Q35703205-51BB3D98-36D9-4FF4-AF12-E8008E3D44DBQ38381584-D82D95F5-592B-4CCA-BCC7-B5AFB6B42DA6Q38630102-8E61C5B8-3EF8-45BD-96BA-31DAEC8A4F1EQ38721242-56621205-DADD-4E91-9069-70C6A9C1FEAFQ38931620-ED578A17-BFE0-4426-B84F-E60EE2861144Q40152237-0EF007D7-35EC-4123-8434-AF8B3C1C7B72Q40196486-14D7FABC-6857-400B-A773-87A86035366CQ41922681-C139B196-02B0-42AA-954D-CD0FE7354459Q42699381-8D8EFC8B-5563-40DF-8362-98C10A20AD2EQ42699385-FD4A7DB3-C45D-4E6C-8C6F-DE398FC5B071Q47556691-8F3F45AC-92AD-480E-B9CA-BBAE8B36713CQ47556909-A93FC5D4-088B-48F5-8D86-71C3E605F9D5Q60404232-AB86AC50-0DD2-485D-A930-CF9670BF574EQ60438873-64E42394-78F9-4E46-81F4-443E11CD89E3Q61953233-62D2DEA3-1E1F-47A2-A885-D8C66CE139E2Q62896060-B62E2186-CE45-4D63-88FA-05FD23A171E8Q63683752-839E1BD0-3499-4A4D-9B4A-838EC3533143Q63683757-2E70D8A8-0C6F-4B25-AE44-52F59AFC8964Q63683759-0956277A-435C-471B-BD77-4E8C92E46722Q90845300-05FE1A67-2241-4E48-A1F7-F127060F0D72Q91065094-A1027281-5753-4822-8B97-30F6BE8A7075Q91565062-E3BE774B-D173-4FCD-A005-4523DD63A893Q91745647-C397B29A-D62F-4E83-B7C0-1D1E67F88672Q91829355-FE45712D-F98C-4254-8943-410EDCE49124Q91989084-98312C44-CD00-42C5-9665-A52A959C9EA8Q92170619-ED0CE64B-2199-4F55-9B67-C40609A66CA9Q92222974-1EF96478-ED71-4EDE-AE5A-A0174CF1B951Q92614866-081052E9-0D1F-4243-A546-5624EB27494FQ92731588-B1806588-6545-4DF1-8073-D28B5DEA724D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Evan B Cunningham
@ast
Evan B Cunningham
@en
Evan B Cunningham
@es
Evan B Cunningham
@nl
type
label
Evan B Cunningham
@ast
Evan B Cunningham
@en
Evan B Cunningham
@es
Evan B Cunningham
@nl
prefLabel
Evan B Cunningham
@ast
Evan B Cunningham
@en
Evan B Cunningham
@es
Evan B Cunningham
@nl
P106
P1153
56396254000
P21
P31
P496
0000-0002-8048-3473